Aktis Oncology, Inc.
Aktis Oncology, Inc.（AKTS）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
akts · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年5月13日
分析师评级与共识
基于过去 3 个月内 7 位华尔街分析师
Buy
7 位分析师
共识
评级分布
12 个月目标价
High
$35.00
Consensus
$33.00
+74.0% upside
Low
$31.00
Median: $33 · Last Close: $18.97
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$33.00
74.0% upside
High Target
$35
84.5%
Low Target
$31
63.4%
Current Price
$18.97
as of today
Based on analyst price targets, the AKTS stock price prediction for the next 12 months ranges from $31 to $35. The consensus AKTS price forecast of $33.00 implies 74.0% upside from the current price of $18.97.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $18.92 | ↓ 0.25% |
1-day model range: $18.8–$19.05. Peak: $19.05 (-0.25%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AKTS · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-01-04 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-09-07 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-09-07 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2023-05-09 | Roth MKM | Maintains | Buy→Buy |
| 2023-05-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-11-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-09-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-03 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Aktis Oncology, Inc. (AKTS) stock. Of the recent 17 rating actions, 1 were upgrades and 4 were downgrades. 7 analysts currently cover AKTS.
分析师推荐趋势
AKTS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$21M
↑ 591.5% YoY
Revenue Next Year
$15M
↓ 28.4% YoY
EPS This Year
$-1.62
EPS Next Year
$-2.28
↑ 40.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast AKTS EPS of $-1.62 for the current fiscal year, based on estimates from 4 analysts. The AKTS revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
AKTS 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。AKTS 的共识目标价为 $33.00（+74.0% 上行空间），分析师共识为 Buy。
AKTS 的短期预测（明日）为 $18.92（-0.25%）。
Aktis Oncology, Inc. 在 NASDAQ 上市，代码 AKTS。AKTS 在 2027 年的整体展望偏积极，在覆盖分析师中约 57% 对应 Buy 共识。
常见问题
AKTS 预测 · 8 个问题根据 7 位华尔街分析师，AKTS 的 12 个月平均目标价为 $33.00，最高 $35.00、最低 $31.00。若有图表，中位目标价可在上方查看。相对当前价 $18.97，隐含约 +74.0% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.